Kota Makassar

Researchers are evaluating the effectiveness, safety, and tolerability of adding metformin to the standard multi-drug therapy (MDT) for patients newly diagnosed with multibacillary leprosy. This double-blind, placebo-controlled Phase 2 trial aims to see if metformin can reduce leprosy reactions, nerve damage, and the need for corticosteroids, while also exploring its effects on immune system markers. The study plans to enroll 166 patients aged 18 to 65 years from leprosy endemic areas in Indonesia. Participants will be randomly assigned to receive either metformin 1000 mg once daily or a placebo for 24 weeks, alongside the standard MDT which continues for 48 weeks. The study compares these two groups to assess how metformin as an additional treatment might influence clinical outcomes. This trial is funded by the Leprosy Research Initiative and follows strict protocols to ensure reliable results. During the 48-week study period, participants will be monitored for leprosy reactions and adverse events, with primary outcomes focused on the proportion experiencing these reactions and side effects. Secondary measures include severity and timing of reactions, the amount of corticosteroids used, and quality of life assessments. Regular evaluations include clinical examinations and safety checks to track the participants' health and treatment adherence throughout the study.

Researchers are comparing the effects of robotic therapy, exergame therapy, and standard rehabilitation on improving hand function in patients who have had a stroke. The study aims to evaluate how these interventions impact functional recovery, changes in Tenascin-C levels, and clinical outcomes over time. This is a randomized controlled trial conducted in two teaching hospitals and one physical rehabilitation center in Makassar among post-stroke patients. Participants are randomly assigned to one of three groups: robotic therapy using Syrebo robotic exoskeletal assistance with mirror therapy and daily living activity training; exergame therapy involving physical exercise through active video games requiring motor skills and coordination; or standard rehabilitation with neurorehabilitation approaches led by a physical therapist. All interventions are provided three times per week for six weeks. During the study, participants undergo assessments before and after the six-week treatment period. Evaluations include motor function of the upper extremity using the Fugl-Meyer Assessment, finger dexterity with the Nine Hole Peg Test, hand strength measured by a dynamometer, and blood tests to measure Tenascin-C levels. Additional data such as cognitive ability, stroke type, and spasticity are also collected. Researchers monitor outcomes and safety throughout the trial to compare the benefits and effects of each therapy.

The HYIMPACT study is a large, observational research project across seven Asian countries designed to understand how Nebilet (nebivolol) works in people with high blood pressure, also called hypertension. It focuses on how Nebilet affects blood pressure control over time, treatment adherence, quality of life, prescription habits, and heart-related outcomes. The study includes about 5,000 adults with newly diagnosed or uncontrolled hypertension, some of whom may have other heart-related conditions. Participants will either start Nebilet treatment or have been on it for no more than two weeks before joining. They will be observed regularly for up to three years, with blood pressure measurements taken at baseline, 12, 24, and 36 months. The study also compares Nebilet used alone versus in combination with other treatments, and examines the relationship between blood pressure readings taken at home and in the clinic. Throughout the study, patients will have their blood pressure monitored, complete questionnaires about medication adherence and quality of life, and provide health information including cardiovascular risk factors and lab test results when available. Researchers will track major heart events like heart attacks and strokes, and record any side effects. Data will be collected electronically to ensure quality and consistency, helping to provide real-world insights about Nebilet's role in managing hypertension over time.